William Lewis

William Lewis sells 10,699 shares at avg $117.40 under 10b5-1 plan; holds 259,058 shares plus 10,700 in options

William Lewis, Chair and CEO, executed 3 separate sales totaling 10,699 shares for $1,256,084.13 on 2026-07-09 at prices ranging from $116.55 to $118.52, all conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-09-04. The sale represents a 4.0% reduction from his pre-transaction holdings of 269,757 shares, leaving him with 259,058 non-derivative shares post-trade plus 10,700 shares remaining in stock option holdings. The stock currently trades at $115.61, within 52 weeks of a $212.75 peak and down 25.3% over the past 90 days, though up 25.8% in the past 30 days. His cross-ticker track record across 20 prior sales shows an average 90-day return of -31.0%, though those outcomes are not directly predictive of this ticker where five prior scheduled sales occurred on 2026-06-25. The company reported $306.0M in quarterly revenue with 66.7% annual growth but net losses of $163.6M in the latest quarter, reflecting continued unprofitability despite strong top-line expansion.

INSM CEO Lewis sells 21,398 shares for $2,210,762.94 via scheduled 10b5-1 plan; stock -51.4% from 52-week high

William Lewis, Chair and CEO of INSMED Inc, executed five separate sales totaling 21,398 shares for $2,210,762.94 on 2026-06-25 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, reducing his non-derivative holdings to 258,917 shares. The stock has declined -51.4% from its 52-week high of $212.75 and is down -28.8% over 90 days, while the company reported a net loss of $163,563,000.00 in its latest quarter despite annual revenue growth of +66.7%. Across his prior five trades at INSM dating back to 2026-05-18, Lewis's sales have been followed by 30-day declines ranging from -6.5% to -8.0%, and his cross-ticker track record shows an average 90-day return of -31.4% after 20 prior sells, indicating a pattern of sales preceding further weakness. However, this transaction is governed by a scheduled 10b5-1 plan rather than discretionary timing, and Lewis retains 21,399 shares in stock option holdings, preserving meaningful derivative exposure to the company's upside.

Chair/CEO William Lewis sells 6,515 shares of INSM at $94.03 under pre-arranged 10b5-1 plan; stock down 56.8% from 52-week high.

William Lewis sold 6,515 shares of INSMED Inc (INSM) on 2026-06-08 at $94.03, reducing his holdings by -2.5% to 258,917 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning it was scheduled rather than discretionary. The stock has declined -11.6% over the past 30 days and -34.2% over the past 90 days, trading -56.8% below its 52-week high of $212.75. INSMED remains unprofitable with net income of $-163.6M despite strong annual revenue growth of +66.7%, generating $306.0M in latest quarterly revenue. Across his prior five sales at INSM, post-trade returns have ranged from -24.2% to -0.4% over 90-day windows, whereas his cross-ticker track record shows an average 90-day return of -22.5% following sales. The scheduled nature of this sale prevents timing-based interpretation; investors should monitor how the stock's recent steep decline and ongoing unprofitability trajectory align with company fundamentals and market conditions.

INSM Chair/CEO Lewis William sold 25,564 shares for $2.7M via scheduled 10b5-1 plan; stock down -49.3% from 52-week high

Lewis William executed 3 separate sales totaling 25,564 shares for $2,718,223.75 on 2026-05-18 under a pre-arranged 10b5-1 trading plan adopted 2025-09-04, reducing his holdings by 8.6%. The company is unprofitable ($-163.6M net income in latest full fiscal year) despite strong revenue growth (+66.7% annually) and a substantial $23.4B market cap. The stock has declined -24.4% over 30 days and -33.0% over 90 days, trading -49.3% below its 52-week high of $212.75. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, the timing reflects pre-established parameters rather than current market judgment. Lewis William's prior 5 sales at INSM (all on 2026-05-04) were followed by declines ranging from -14.5% to -17.2% over both 30- and 90-day periods, consistent with his broader cross-ticker track record showing an average 90-day return of -20.1% after his 20 prior sales.

INSM Chair & CEO Lewis William exercises options and sells 10,699 shares in net-neutral transaction, extending a consistent sell pattern at this ticker.

Lewis William, Chair and CEO of Insmed, executed a classic exercise-and-sell transaction — acquiring shares through two option exercises and immediately disposing of the same number of shares on the open market, leaving his net holdings unchanged. This filing represents his sixth through eleventh open-market sales at INSMED in the three-year window, continuing a pattern of consistent selling at this company. What makes this worth watching is his prior track record: across all five of his previous open-market sales at INSMED with measurable outcomes, the stock declined afterward in both the near term and over a longer horizon — meaning every prior exit proved well-timed at both the 30-day and 90-day mark. He executed the current sales while Insmed's stock trades well below its 52-week high and has declined significantly over both the past month and the prior three months. On the fundamentals side, the company is not yet profitable, though it has posted strong revenue growth year-over-year, which creates a mixed backdrop. The persistent sell pattern from the company's top executive, combined with a historically accurate exit record, makes this filing more notable than a typical exercise-and-sell would otherwise suggest.

Chair/CEO Lewis William sells 10,699 shares in 4 separate transactions for $1,540,331.72; post-transaction holdings 301,185 shares

Lewis William, Chair and CEO of INSMED, executed 4 separate open-market sales on 2026-04-16 totaling 10,699 shares for $1,540,331.72, reducing his holdings by 3.4% to 301,185 shares. The transaction prices ranged from $142.99 to $145.79, clustering near the current price of $144.48. This sale occurs amid significant company volatility: INSM is down 31.7% from its 52-week high of $211.41, though the stock is up 1.2% over the prior 30 days. The company is currently unprofitable (net income of $-370.0M in the latest quarter) despite strong revenue growth of 66.7% year-over-year. Prior to this filing, Lewis William executed three separate sell transactions at INSM on 2026-04-06 and 2026-03-19, indicating active share reduction over recent weeks. His cross-ticker track record shows 20 prior sales with an average 30-day return of -1.3%, though timing outcomes at INSM specifically remain not yet measurable.

CEO Lewis William sold 10,699 shares at blended average $163.22; retains 301,185 shares post-transaction.

Lewis William, Chair and CEO of INSMED Inc, executed three separate sales on 2026-04-06 totaling 10,699 shares for $1,746,335.79 at prices ranging from $161.73 to $164.01. The blended average sale price of $163.22 is above the current market price of $160.18, and occurs after two recent sell transactions at the same ticker on 2026-03-19 and 2026-03-05 (the latter pair of which posted 30-day returns of +11.8% and +10.1% respectively). The company is unprofitable with net income of $-370.0M on revenue of $142.3M in the latest quarter, though it reported annual revenue growth of +66.7% year-over-year. Post-transaction, the CEO retains 301,185 shares (-3.4% vs pre-transaction holdings of 311,884 shares), maintaining substantial equity exposure. The series of sales within the past month—both at the ticker and in aggregate—warrants monitoring for additional context on the company's strategic direction and capital allocation, particularly given the negative profitability backdrop.

CEO Lewis William sold 10,699 shares for $1,535,542.10 across 3 transactions on 2026-03-19; stock down 10.0% in 30 days and 22.2% in 90 days.

Lewis William, Chair and CEO, executed 3 separate sales on 2026-03-19 totaling 10,699 shares (10.7K shares) for $1,535,542.10 ($1.5M) at a blended average price of $143.52, reducing his holding from 311.9K to 301.2K shares (-3.4%). The stock has since declined 10.0% over the prior 30 days and 22.2% over the prior 90 days, now trading at $136.00, which is 35.7% below the 52-week high of $211.41. The company reported recent quarterly revenue of $142.3M with annual growth of +66.7%, but remains unprofitable with a full-year net income of -$370.0M. Lewis William sold at prices ($142.17, $143.42, $144.11) that proved higher than current market levels, though his cross-ticker historical sell record shows an average 30-day return of -4.4% across 20 prior open-market sales. Recent prior trades at INSM on 2026-03-05 and 2026-02-19 do not yet have measurable 30- or 90-day outcomes.

INSM Chair/CEO Lewis William sold 10,699 shares for $1,562,327.58 via scheduled 10b5-1 plan (Sept 2025).

Lewis William, Chair and CEO of INSMED Inc, executed 4 separate sales totaling 10,699 shares for $1,562,327.58 at prices ranging from $144.23 to $147.54 on 2026-03-05. This sale reduced his holdings from 311,884 shares to 301,185 shares, a 3.4% reduction. Critically, this transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning the sale was scheduled and automatic rather than discretionary. Under a 10b5-1 plan, the timing and structure of sales are predetermined, so this filing reflects plan execution rather than a deliberate market-timing decision by the executive. Investors should note that the 10b5-1 framework does not inherently signal confidence or concern—it is a disciplined mechanism for executives to diversify holdings while complying with insider trading restrictions.

Chair/CEO Lewis William sold 10,699 shares ($1.6M) across 5 transactions on 2026-02-19 under 10b5-1 plan.

Lewis William, Chair and CEO of INSM, executed 5 separate sales totaling 10,699 shares for $1,615,256.86 at a blended average price of $150.97 per share on 2026-02-19. This activity is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning the transactions were scheduled rather than discretionary trading decisions. Post-sale holdings of 301,185 shares represent a 3.4% reduction from pre-transaction holdings of 311,884 shares. As a scheduled plan execution, this filing reflects predetermined liquidity management rather than a signal derived from current market conditions or company outlook.